Methods of modulating inflammasome activity to treat inflammatory conditions

Method for the detection of inflammasome proteins as biomarkers of neurological disorders

Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases

Methods of modulating inflammasome activity to treat inflammatory conditions

Method for the detection of inflammasome proteins as biomarkers of neurological disorders

A molecular platform in neurons regulates inflammation after spinal cord injury

 

Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury

Exosome-mediated inflammasome signaling after central nervous system injury

 

Traumatic Brain Injury-Induced Acute Lung Injury: Evidence for Activation and Inhibition of a Neural-Respiratory-Inflammasome Axis

The Role of Non-canonical and Canonical Inflammasomes in Inflammaging

Differential expression of inflammatory and angiogenic factors in thrombi, cerebral and peripheral plasma following acute large vessel occlusion stroke

 

Biomarkers
 Inflammatory Biomarkers of Traumatic Brain Injury

The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer's Disease

 Inflammasome Proteins As Biomarkers of Multiple Sclerosis


 

 Inflammasome Proteins in Serum and Serum-Derived Extracellular Vesicles as Biomarkers of Stroke

Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response

Renal and Inflammatory Proteins as Biomarkers of Diabetic Kidney Disease and Lupus Nephritis

Inflammasome Proteins as Inflammatory Biomarkers of Age-Related Macular Degeneration

ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis


 

Literature Review
Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury

 

Therapeutics targeting the inflammasome after central nervous system injury

Neural-respiratory inflammasome axis in traumatic brain injury

The Inflammasome in Reproductive Biology: A Promising Target for Novel Therapies

Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets

The Inflammasome in Times of COVID-19

IC 100 binds to ASC specks and ASC-containing inflammasomes intracellularly and extracellularly, thus inhibiting inflammasome activation, which results in decreased levels of the pro-inflammatory cytokines IL-1 beta and IL-18.

Compositions and methods for treating inflammasome-related diseases or conditions

Technology

IC 100

InflamaCORE, LLC has developed IC100, a humanized monoclonal IgG4 antibody with a long half-life with a binding kinetics in the subnanomolar range that acts intracellularly and extracellularly and it has been shown to inhibit the inflammasome in animal models of spinal cord injury, traumatic brain injury, acute lung injury, multiple sclerosis and inflammaging.

Innate immune proteins as biomarkers for CNS injury

Methods and compositions for treating virus-associated inflammation

Intellectual Property

Therapeutics

Compositions and methods for treating inflammasome-related diseases or conditions

Methods for modulating inflammasome activity and inflammation in the lung

Innate immune proteins as biomarkers for CNS injury

Methods for modulating inflammasome activity and inflammation in the lung

Compositions, methods and kits for detecting and treating alzheimer's disease

InflamaCORE, LLC has a robust pipeline of drugs that include:  humanized monoclonal antibodies and small molecule inhibitors that target inflammasome signaling molecules.  These drugs provide additional tools to treat a variety of inflammatory diseases.  

Methods and compositions for treating virus-associated inflammation

KEY PUBLICATIONS IN RESEARCH AREAS OF INTEREST

Pipeline